Osteoarthritis Treatments, Revealed During A Genetic Study

Osteoarthritis Treatments, Revealed During A Genetic Study
SHARE

Researchers at the Wellcome Sanger Institute, GSK, and their collaborators carried out the most comprehensive genetic study of osteoarthritis to date. In the research, the scientists noticed that 52 new genetic changes are connected to the condition.

To reach those findings, the researchers analyzed data from the genomes of over 77,000 people with osteoarthritis. The study’s report was issued in the Nature Genetics journal. The research is useful for experts to estimate the real benefits of osteoarthritis treatments.

Osteoarthritis is affecting tens of millions of people around the world, and it is a condition that affects the joints and causes them to deteriorate and cause pain. The disease has no treatment at the moment, but the doctors address it with medication to relief from pain and reduce inflammation. Besides, osteoarthritis is the leading cause for disability worldwide. Thanks to the new genetic study, new roads to osteoarthritis treatment were open.

New Genetic Study Revealed Osteoarthritis Treatments

“Osteoarthritis is a very common, disabling disease with no cure. We have conducted the largest study of osteoarthritis to date and found over 50 new genetic changes that increase the risk of developing osteoarthritis. This is a major step forward in developing treatments to help the millions of people suffering from the disease,” explained Professor Eleftheria Zeggini.

Ten of the genes involved in osteoarthritis are already the target of “existing drugs, which are either in clinical development or approved for use against osteoarthritis and other diseases,” reported MedicalXPress.

“Osteoarthritis affects over 8.5 million people across the UK. We know that the condition impacts people in different ways, meaning the treatment that works for one person doesn’t always work for someone else,” said Dr. Stephen Simpson. “This study represents a hugely important milestone towards understanding the complexity of osteoarthritis and finding new treatments, and we are delighted that our support for the arcOGEN study has helped deliver this. In the long term, the research progresses us significantly on the journey to ending the pain, isolation, and fatigue of those living with arthritis,” he added.


SHARE

Share this post

Post Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.